Based on our understanding of receptor tyrosine kinase-MAPK signaling, and our preliminary analysis of 115 endometrial tumors, we anticipated that FGFR2 and KRAS mutations would occur in a mutually exclusive pattern. The gene discussed is FGFR2; the disease is endometrium neoplasm.